Loading
MC
Medite Cancer Diagnostics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ABELES JOHN H, was filed 23 Oct 2018.
Medite Cancer Diagnostics, Inc.: what insiders have been doing
Every trade that managers of Medite Cancer Diagnostics, Inc. disclose to SEC (Form 4) is tracked on this page. No insider at Medite Cancer Diagnostics, Inc. has published a filing in the past twelve months. The most recent one dates from 23 October 2018.
Our records for Medite Cancer Diagnostics, Inc. go back to 2006, with 93 purchases and no sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
113
Thresholds
n/a
Buy Volume
€4M
93 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +32.4%Entry US$0.05 · Close at T+365 US$0.07
- -65.5%Entry US$0.20 · Close at T+365 US$0.07
- -82.5%Entry US$0.15 · Close at T+365 US$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$3.7M
Valuation
P/Book0.0x
Beta493.77
Balance sheet & cash
Debt / Equity94%
Profitability & ownership
ROE-73.7%
ROA-13.7%
% institutions0.0%
Last declaration on 23 October 2018
Declarations113 total
40,000 sharesCommon StockSEC:0001415889-18-001538:0
266,667 shares@ US$0.07540.1% of flowCommon StockSEC:0001415889-18-001538:1
Canonical exit: 9 Jan 2019 (T+90)
8,973,333 shares@ US$0.07523.9% of flowCommon StockSEC:0001415889-18-001512:0
Canonical exit: 13 Jan 2019 (T+90)
80,000 shares@ US$0.0750.2% of flowCommon StockSEC:0001415889-18-001512:1
Canonical exit: 13 Jan 2019 (T+90)
1,100,000 shares@ US$0.0752.9% of flowCommon StockSEC:0001415889-18-001194:0
Canonical exit: 23 Oct 2018 (T+90)
133,333 shares@ US$0.075100.0% of flowCommon StockSEC:0001415889-18-001192:0
Canonical exit: 25 Oct 2018 (T+90)
6,933,333 shares@ US$0.07518.2% of flowCommon StockSEC:0001415889-18-001111:0
Canonical exit: 7 Oct 2018 (T+90)
400,000 shares@ US$0.0751.0% of flowCommon StockSEC:0001415889-18-001111:1
Canonical exit: 7 Oct 2018 (T+90)
400,000 shares@ US$0.07559.9% of flowCommon StockSEC:0001415889-18-001103:0
Canonical exit: 1 Oct 2018 (T+90)
8,000,000 shares@ US$0.07520.4% of flowCommon StockSEC:0001415889-18-001080:0
Canonical exit: 25 Jul 2018 (T+90)
1,333,334 shares@ US$0.0753.6% of flowCommon StockSEC:0001415889-18-001080:1
Canonical exit: 26 Sept 2018 (T+90)
1,333,334 shares@ US$0.75100.0% of flowCommon StockSEC:0001415889-18-000694:0
Canonical exit: 3 Jul 2018 (T+90)
10,666,667 shares@ US$0.07526.6% of flowCommon StockSEC:0001415889-18-000207:0
Canonical exit: 7 May 2018 (T+90)
1,333,333 shares@ US$0.0753.4% of flowCommon StockSEC:0001415889-18-000207:1
200,000 shares@ US$0.81100.0% of flowCommon StockSEC:0001415889-17-001795:0
156,250 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-15-036873:0
Canonical exit: 3 Jan 2016 (T+90)
156,250 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-15-036873:1
Canonical exit: 3 Jan 2016 (T+90)
156,250 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-15-036871:0
Canonical exit: 3 Jan 2016 (T+90)
156,250 sharesCommon Stock, par value $0.001 per shareSEC:0001140361-15-036871:1
Canonical exit: 3 Jan 2016 (T+90)
919,234 shares@ US$0.0155Common StockSEC:0001144204-13-031775:0
162,500,000 shares@ US$0.02Common StockSEC:0001144204-13-031086:0
1,301,353 shares@ US$0.02Common StockSEC:0001144204-12-036869:0
Canonical exit: 24 Sept 2012 (T+90)
2,187,500 shares@ US$0.015Common StockSEC:0001144204-12-009540:0
Canonical exit: 14 May 2012 (T+90)
10,000 shares@ US$0.55Common Stock, $.001 par valueSEC:0001209191-09-024508:0
Canonical exit: 11 Jun 2009 (T+90)
11,000 shares@ US$0.52Common Stock, $.001 par valueSEC:0001209191-09-024508:1
Canonical exit: 14 Jun 2009 (T+90)
25 of 113 declarations
About Medite Cancer Diagnostics, Inc.
Medite Cancer Diagnostics, Inc. is a company focused on developing diagnostic solutions for cancer. It aims to enhance methods for cancer detection and treatment.
